Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone

PartnershipDatrowayPositive

AI Analysis

Summary

Summit Therapeutics entered a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to test its Trop-2-directed antibody-drug conjugate (Datroway) for cancer. Eccogene earned a $50M milestone payment.

Clinical Trial Data

Importance:6/10

Sentiment:

0.50

partnershipclinical trialcancerantibody-drug conjugatemilestone

Related Companies

$AZN $DSKYF $REGN

Read the original article

Published by Endpoints News on October 2, 2026 2:48 PM

Read Original